Results are far from perfect, but they are promising.
All that is to say that given last year's Aduhelm spectacle, you'd be forgiven for doubting what appears to be a promising development in Biogen's continued Alzheimer's drug development. And that's just whatwith a collaborator, fellow pharmaceutical maker Eisai, on Tuesday. But that being said, initial data suggests that the new drug is actually proving quite successful in late-stage clinical trials — enough so that Biogen might have a redemption arc, after all.
There are some caveats. As with other anti-amyloid medications, some patients experienced brain swelling or even bleeding, and some experts have already raised concerns over the study's significance.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Alzheimer's drug study yields positive results, say makers Eisai and BiogenAn experimental Alzheimer's drug made by Eisai Co. Ltd. and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
Leer más »
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Leer más »
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNNA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Leer más »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Leer más »
Alzheimer's drug shows promise in early results of studyJapan's Eisai Co. said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. abc15
Leer más »
Alzheimer's Treatment Shows Promise in Early Results of Study, Drugmaker SaysBiogen and Japan’s Eisai Co. said early results showed that the treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo after 18 months of the infused treatment.
Leer más »